论文部分内容阅读
目的观察分析靶向治疗对复发性耐药性卵巢癌的治疗价值。方法 84例复发性耐药性卵巢癌患者,随机分为观察组(43例)和对照组(41例)。对照组患者单一使用铂类+紫杉醇化疗,观察组患者采用铂类+紫杉醇化疗方案联合贝伐单抗治疗。对比两组患者治疗后的效果、患者的生存时间以及不良反应发生率。结果观察组RECIST和CA125的客观有效率分别为41.86%、44.19%,明显优于对照组的19.51%、21.95%,差异有统计学意义(P<0.05)。对照组患者不良反应发生率为19.51%(3例恶心、呕吐、1例高血压、2例心律失常、2例中性粒细胞减少);观察组患者的不良反应发生率为20.93%(2例恶心、呕吐、2例高血压、3例心律失常、2例中性粒细胞减少),两组比较差异无统计学意义(P>0.05)。观察组无疾病进展生存时间为(16.12±3.5)个月,对照组无疾病进展生存时间为(9.54±4.80)个月,观察组无疾病进展生存时间长于对照组(P<0.05)。结论靶向治疗联合化疗优于单纯化疗,值得推荐用于复发耐药(难治)卵巢癌。
Objective To observe the therapeutic value of targeted therapy on recurrent resistant ovarian cancer. Methods Eighty-four patients with recurrent drug-resistant ovarian cancer were randomly divided into observation group (43 cases) and control group (41 cases). Patients in the control group were treated with platinum plus paclitaxel alone. Patients in the observation group were treated with platinum plus paclitaxel chemotherapy plus bevacizumab. The effect of two groups of patients after treatment, the survival time of patients and the incidence of adverse reactions were compared. Results The objective effective rates of RECIST and CA125 in the observation group were 41.86% and 44.19%, respectively, which were significantly better than those in the control group (19.51% and 21.95%, respectively) (P <0.05). The incidence of adverse reactions in the control group was 19.51% (nausea and vomiting in 3 cases, hypertension in 1 case, arrhythmia in 2 cases and neutropenia in 2 cases). The adverse reaction rate in the observation group was 20.93% (2 cases Nausea, vomiting, 2 cases of hypertension, 3 cases of arrhythmia, 2 cases of neutropenia). There was no significant difference between the two groups (P> 0.05). The progression-free survival time was (16.12 ± 3.5) months in the observation group and (9.54 ± 4.80) months in the control group. The progression-free survival time in the observation group was longer than that in the control group (P <0.05). Conclusion Targeted chemotherapy combined with chemotherapy is superior to chemotherapy alone and is recommended for relapse-resistant (refractory) ovarian cancer.